C.E.M. Griffiths

Top papers

• Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

  Rosa Parisi, Deborah Symmons, C.E.M. Griffiths, et al.·2012·Journal of Investigative Dermatology
  ↗ 2,555
• Psoriasis

  C.E.M. Griffiths, April W. Armstrong, Jóhann E. Guðjónsson, et al.·2021·The Lancet
  ↗ 2,150
• Pathogenesis and clinical features of psoriasis

  C.E.M. Griffiths, Jonathan NWN Barker·2007·The Lancet
  ↗ 2,094
• Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

  Richard G. Langley, Boni E. Elewski, Mark Lebwohl, et al.·2014·New England Journal of Medicine
  ↗ 1,947OA
• Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

  Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, et al.·2017·The Lancet
  ↗ 1,224OA
• National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study

  Rosa Parisi, Ireny Iskandar, Evangelos Kontopantelis, et al.·2020·BMJ
  ↗ 1,120OA
• A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1

  Amy Strange, Gavin Band,  Peter Donnelly, et al.·2010·Nature Genetics
  ↗ 1,054OA
• Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity

  Lam C. Tsoi, Sarah L. Spain, Jo Knight, et al.·2012·Nature Genetics
  ↗ 1,042
• Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

  Kristian Reich, Frank O. Nestlé, Kim Papp, et al.·2005·The Lancet
  ↗ 1,041
• Definition of treatment goals for moderate to severe psoriasis: a European consensus

  Ulrich Mrowietz, Knud Kragballe, Kristian Reich, et al.·2010·Archives of Dermatological Research
  ↗ 878OA
• Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

  C.E.M. Griffiths, Bruce Strober, Peter van de Kerkhof, et al.·2010·New England Journal of Medicine
  ↗ 848
• Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

  Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, et al.·2017·Journal of the American Academy of Dermatology
  ↗ 846OA